Nowhere is this opportunity for convergence more apparent than in the treatment of two of the leading causes of blindness. Glaucoma and cataracts frequently coexist, with approximately 1 million cataract procedures performed annually on patients in the United States who also have glaucoma,1,2 yet their treatment paradigms have historically remained separate and often fragmented.
What if, instead of treating these conditions separately, we approached them through a single, integrated system? Before the iPhone, consumers carried separate devices for communication, music, and internet access. Apple transformed the experience by seamlessly combining those three functions into one intuitive platform. We believe the same principle can apply in ophthalmology: integrating proven technologies in a way that simplifies care, fits naturally into existing workflows, and delivers greater value for both physicians and patients. Innovation seemingly so straightforward that in retrospect, we wonder why no one had thought of it before.
That’s the vision behind SpyGlass Pharma®’s investigational Bimatoprost Drug Pad-Intraocular Lens (BIM-IOL) System, designed to treat glaucoma and cataracts simultaneously. By combining drug-eluting pads containing the glaucoma medication bimatoprost with a monofocal intraocular lens (IOL) implanted during routine cataract surgery, the BIM-IOL System is designed to enable any cataract surgeon to address the two diseases at once without additional surgical tools or training beyond routine cataract surgery. SpyGlass Pharma has initiated two registrational Phase III clinical trials of its BIM-IOL System and is working with the U.S. Food and Drug Administration (FDA) to advance the program through completion of Phase III clinical trials, eventual New Drug Application submission, and ultimately to potential FDA approval.
Cataract and glaucoma surgeons are passionate about sustained drug delivery's potential to redefine the standard of care for glaucoma patients. Two sustained drug delivery options are currently on the market, each with its own trade-offs. Durysta (Allergan/AbbVie) is a drug depot injected into the anterior chamber that does not require gonioscopy or angle surgery; however, it provides shorter drug delivery duration, is labeled for a single administration per eye, and carries a warning about corneal endothelial cell loss.3,4 iDose TR (Glaukos) provides long-duration drug delivery and is now labeled for re-administration in patients who maintain a healthy cornea,5–7 but its placement requires an angle-based procedure similar to MIGS. Only about one-third of the 10,000 active cataract surgeons in the United States routinely perform MIGS surgeries (defined as at least two procedures per month), creating a significant barrier to access.2,8 By embedding the drug-delivery system into the IOL, SpyGlass Pharma seeks to advance that progress even further, making it possible for all cataract surgeons to treat glaucoma without the burden of daily eye drops or additional, specialized procedures.
Simplifying Care with Integrated Therapies
To appreciate where ophthalmic innovation is heading, it’s important to reflect on where it’s been. Prostaglandin analog eye drops remain highly effective at lowering intraocular pressure (IOP) in glaucoma, but their success relies entirely on patients’ ongoing compliance. For many caregivers and glaucoma patients, who are often elderly people with dexterity or memory issues, that’s a big ask that can quietly erode quality of life. Additionally, daily drops can be uncomfortable or even painful, making compliance extremely challenging.
When drops fail to adequately control IOP, surgical intervention or MIGS devices may be recommended. While MIGS devices have expanded the treatment landscape with less-invasive approaches, results of such procedures can vary significantly from patient to patient, making it difficult for surgeons to predict which patients will achieve long-term IOP control. Outcomes may be affected by variations among individual anatomy, disease severity, and possible scar tissue formation leading to surgical failure.9–13 Additionally, MIGS requires specialized techniques and training that can present technical and workflow barriers for the majority of surgeons.
Cataracts, by contrast, are treated with a relatively common surgical procedure. Each year in the U.S., surgeons perform approximately 1 million cataract surgery procedures in patients who also have glaucoma,2 presenting a significant opportunity to help people affected by both conditions. Since providers with general cataract surgery skills won’t need additional specialized techniques or training to use it, the BIM-IOL System is aimed at helping keep patient and provider burdens in check while restoring vision, providing lasting IOP control, and expanding access to sustained-release of bimatoprost.
Elevating Care: Clinical Effectiveness Meets Ease of Adoption
In looking at medical innovation, what separates a merely promising idea from one that successfully establishes a new standard of care? The answer lies at the intersection of clinical effectiveness and ease of adoption.
The investigational BIM-IOL System was designed with that balance in mind. For patients, the BIM-IOL System is implanted through a single, familiar procedure in the form of standard cataract surgery. The breakthrough comes after the surgery, in the delivery of lasting IOP control for three years, without the need for daily eye drops in 98% of cases based on interim 12-month data from SpyGlass Pharma’s Phase 1/2 trial14 – potentially reducing the burden and anxiety associated with this medical task that affects many glaucoma patients.
For providers, there is no need to utilize new surgical equipment for the implant and no steep learning curve, as the BIM-IOL System can be implanted as part of a routine cataract surgery. And the BIM-IOL System removes the burden of patient adherence, which remains a major impediment to proper therapy with traditional topical drops.14,15
Just as Apple integrated three known user experiences into one revolutionary product, we believe the BIM-IOL System similarly brings together three familiar components into one solution: a known glaucoma drug, a known procedure in cataract surgery, and an IOL built on established lens technology, utilizing the same glistening-free hydrophobic acrylic material licensed to Bausch + Lomb for its enVista® IOL line. Together, these components have the potential to restore vision from cataracts and protect vision from glaucoma in a single, streamlined intervention, opening the door to long-term clinical outcomes and the scale needed to redefine the standard of care.
Emerging Innovations in Ophthalmic Care
As we look to the next phase of innovation in ophthalmic medicine, the overarching theme is developing long-lasting solutions that reduce care burdens. For decades, the trend in medicine has been about minimizing patient burden, moving from highly invasive interventions and high-maintenance therapies toward long-lasting, “set-it-and-forget-it” solutions. In ophthalmology, this effort requires innovations that drive compliance and actively help patients preserve their vision without the burden of daily medical tasks.
Additional research and development efforts are underway to further extend the duration of sustained drug delivery systems and broaden the range of available pharmacological options. By building on prior innovations, sustained drug-delivery platforms may eventually expand to incorporate additional therapeutic options, creating the potential to target multiple ophthalmic conditions simultaneously.
We believe ophthalmology is ready to meet its “iPhone moment,” a turning point defined not by reinventing treatment but by seamlessly integrating proven therapies into smarter, more intuitive systems. This will mark a pivotal point in ophthalmic care, as the field develops solutions that balance the needs of patients and providers and become essential tools in standard practice.
SpyGlass Pharma is a trademark of SpyGlass Pharma, Inc. Other company and product names may be trademarks of the respective companies with which they are associated.
Disclosures: Dr. Eric Donnenfeld is a paid consultant to SpyGlass Pharma. Dr. Malik Y. Kahook is a director and officer of, and holds an ownership interest in, SpyGlass Pharma. Dr. Kahook receives consulting fees and patent royalties from SpyGlass Pharma, New World Medical, and Alcon. The views expressed in this article are those of the authors.
Forward-looking statements contained in this article, including those related to the potential of the BIM-IOL System to become the new standard of care for cataracts patients with glaucoma, are subject to risks and uncertainties. For important information concerning these risks and uncertainties, please visit: https://ir.spyglasspharma.com/forward-looking-statements.
